直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Megan L. Meyers
Associate
More
vCard
  • 271 17th Street, NW
  • Suite 1400
  • Atlanta, GA 30363-6209
+1 404 653 6565
megan.meyers@finnegan.com megan.meyers@finnegan.com

Megan L. Meyers

Associate

  • +1 404 653 6565 +1 404 653 6565
  • megan.meyers@finnegan.com megan.meyers@finnegan.com
  • 271 17th Street, NW
  • Suite 1400
  • Atlanta, GA 30363-6209
  • vCard

Megan Meyers focuses on patent litigation, specifically Abbreviated New Drug Application (ANDA) matters at the district court level and in appeals to the U.S. Court of Appeals for the Federal Circuit. She has experience representing pharmaceutical patent holders in ANDA and 505(b)(2) application litigations arising under the Hatch-Waxman Act. Megan also has substantial litigation experience involving biologics and gene therapy treatments. Her practice spans all phases of patent litigation, including managing discovery; defending fact and expert depositions; developing patent infringement and validity arguments; writing post-trial briefs and dispositive motions; and preparing and examining witnesses at trial. 

Megan holds leadership positions in various organizations, including serving as the vice chair of the Food & Drug Committee for the American Intellectual Property Law Association (AIPLA). She uses her knowledge of the Food & Drug Administration (FDA) and Orange Book procedures to assist in client counseling regarding these topics.

Prior to her legal career, Megan worked in a prosthetics and orthotics lab, where she gained experience with the fabrication of various medical devices. During law school, Megan completed a certificate program focused on advising biology Ph.D. students on intellectual property matters, including obtaining protection for their technologies and analyzing the commercialization of these innovative technologies. Megan also worked as an analyst for an angel investing group that evaluated startup companies for investment potential, including the strength of their patent portfolios.

Megan has a passion for pro bono work. While in law school, she worked with the Health Law Partnership, a branch of Atlanta Legal Aid that partners with impoverished families and children who are patients at Children’s Healthcare of Atlanta. Her work with these families included addressing landlord/tenant issues, Supplemental Security Income (SSI), disability, and family law matters. Megan also successfully represents injured veterans, including writing several briefs to file with the U.S. Court of Appeals for Veterans Claims on behalf of these veterans.

Et Cetera

  • Emory Law Moot Court Society, executive director of special teams, 2017-2018.
  • Legal Association for Women Students, Secretary, 2016-2017; conference chair, 2015-2016.
  • Dean’s Book Award for Trade Secrets.

Experience

Promptu Systems Corporation v. Comcast Corporation

Obtained a $240 million jury verdict for client Promptu in a patent infringement lawsuit against Comcast. The jury found that Comcast willfully infringed Promptu’s patents covering voice recognition technology for TV.

2:16-cv-06516, E.D. Pa., Judge Sanchez
22-1939, Fed. Cir., Judges Prost, Moore, Taranto

Incyte Corporation et al. v. Sun Pharmaceutical Industries Limited et al.

Successfully represented Incyte in patent litigation, including preliminary injunction proceedings related to Sun Pharmaceuticals’ deuterated Janus kinase (JAK) inhibitor, LEQSELVI™. Case settled favorably for our client.

2:24-cv-06944, D.N.J., Judge Padin

Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.

Successfully defended Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.

1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews

AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc.

Represented AstraZeneca in Abbreviated New Drug Application (ANDA) litigation against Zydus on its blockbuster Farxiga® pharmaceutical drug product. After a bench trial, Judge Andrews ruled that the defendant failed to prove that any of the patent claims at issue were invalid due to obviousness, resulting in a complete win for our client. That decision was not ultimately appealed.

1:18-cv-00664, D. Del., Judge Andrews

Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.

Trial counsel for Novartis in district court litigation against multiple generics related to KISQALI ®, a blockbuster, breakthrough CDK4/6-inhibitor for the treatment of breast cancer. After a bench trial, the case resulted in a favorable settlement for our client, supporting patent protection at least until 2031.

1:21-cv-00870, D. Del., Judge Hall

Insights

Federal Circuit IP Blog

Federal Circuit Affirms-in-Part and Vacates-in-Part PTAB Unpatentability Findings Based on Claim Construction Federal Circuit Affirms-in-Part and Vacates-in-Part PTAB Unpatentability Findings Based on Claim Construction

October 27, 2025

Webinar

Patent Eligibility and Engineered Natural Products: Overcoming 101 Challenges, Leveraging Options for IP Protection Patent Eligibility and Engineered Natural Products: Overcoming 101 Challenges, Leveraging Options for IP Protection

April 17, 2025

Webinar

Lecture

Intellectual Property Protection Intellectual Property Protection

March 27, 2024

Athens

At the PTAB Blog

Board Reaffirms that Assignor Estoppel Does Not Bar Assignor from Filing IPR Petition Board Reaffirms that Assignor Estoppel Does Not Bar Assignor from Filing IPR Petition

December 21, 2022

Conference

ACS Fall 2022 ACS Fall 2022

August 21-25, 2022

Chicago

Articles

Smart Baby Monitors May Be Considered Medical Devices by FDA

Smart Baby Monitors May Be Considered Medical Devices by FDA Smart Baby Monitors May Be Considered Medical Devices by FDA

June 16, 2022

More

News

Award/Ranking

61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll 61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll

May 7, 2026

Media Mention

Comcast Hit With $240M Verdict in Voice Recognition IP Trial Comcast Hit With $240M Verdict in Voice Recognition IP Trial

January 27, 2026

Law360

Award/Ranking

56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll 56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll

April 24, 2025

DC Bar

Media Mention

NJ Judge Blocks Sun Pharma from Launching Hair Loss Drug NJ Judge Blocks Sun Pharma from Launching Hair Loss Drug

November 4, 2024

Law360

Press Release

46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll 46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll

June 3, 2022

Media Mention

Litigators of the Week: Shout Out Litigators of the Week: Shout Out

October 22, 2021

The AmLaw Litigation Daily

Professional Activities

  • Order of Emory Advocates
  • Order of the Coif
Admissions and Education

Admissions

  • U.S. Patent and Trademark Office
  • Georgia
  • U.S. Court of Appeals, Federal Circuit

Education

Emory University School of Law
J.D., high honors, 2018
University of Georgia
B.S., Psychology, magna cum laude, 2014
University of Georgia
B.S., Biology, magna cum laude, 2014

Megan's Practices

Global IP Enforcement, Litigation, and Trials
Branded Hatch-Waxman (ANDA) Litigation and Trials

Megan's Industries

AI, Electronics, and Information Technology
Augmented Reality/Virtual Reality (AR/VR)
Chemicals, Industrials, and Materials
Chemical
Hospitality, Gaming, and Leisure
Gaming
Life Sciences
Biologics
Medical Device and Diagnostics
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP